The Wall Street Journal is reporting that Actavis could be up for sale in the coming weeks. The private equity firms backing Actavis have had financial difficulties with the stock market declines.
Ironically, I was talking with some industry folks in New York last week and this came up. There’s definitely interest from Pfizer to expand it’s generic market presence.
It will be interesting to see who eventually snatches up Actavis.
